Progression of atrophy in the whole brain and in areas targeted by AD (medial temporal lobe, temporoparietal, and restrosplenial cortex) represents a reliable marker of the neurodegenerative process underlying clinical symptoms, more robust than amyloidosis alone.
![[This page as RDF]](http://data.gesis.org/somesci/static/rdf-icon.gif){kind=icon}